Catalysts, we still have Brilacidin OM interim data, Prurisol interim data, full brilacidin OM data and the kevetrin trial by years end and likely full prurisol data in Q1 unless it gets finished by year end.

Please correct me if I'm off a bit.

Looks to me the UP's trial was significantly significant.
Like how the release came after close. That was EXCELLENT!! As much as I hate gaps, I hope this puppy gaps up nicely!